JP2023518035A5 - - Google Patents
Info
- Publication number
- JP2023518035A5 JP2023518035A5 JP2022555625A JP2022555625A JP2023518035A5 JP 2023518035 A5 JP2023518035 A5 JP 2023518035A5 JP 2022555625 A JP2022555625 A JP 2022555625A JP 2022555625 A JP2022555625 A JP 2022555625A JP 2023518035 A5 JP2023518035 A5 JP 2023518035A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound according
- inhibitor
- halo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/079464 | 2020-03-16 | ||
| PCT/CN2020/079464 WO2021184154A1 (en) | 2020-03-16 | 2020-03-16 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| PCT/US2021/022322 WO2021188417A1 (en) | 2020-03-16 | 2021-03-15 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518035A JP2023518035A (ja) | 2023-04-27 |
| JP2023518035A5 true JP2023518035A5 (enExample) | 2024-03-27 |
| JP7744358B2 JP7744358B2 (ja) | 2025-09-25 |
Family
ID=77767943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555625A Active JP7744358B2 (ja) | 2020-03-16 | 2021-03-15 | 急性骨髄性白血病の再発を処置または阻害するための化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11963960B2 (enExample) |
| EP (1) | EP4121430A4 (enExample) |
| JP (1) | JP7744358B2 (enExample) |
| KR (1) | KR20220154164A (enExample) |
| CN (1) | CN115298180B (enExample) |
| AR (1) | AR121570A1 (enExample) |
| AU (2) | AU2020436612A1 (enExample) |
| BR (1) | BR112022018345A2 (enExample) |
| CA (1) | CA3168988A1 (enExample) |
| IL (1) | IL296296A (enExample) |
| MX (1) | MX2022011407A (enExample) |
| PE (1) | PE20230461A1 (enExample) |
| PH (1) | PH12022552169A1 (enExample) |
| TW (1) | TWI899184B (enExample) |
| WO (2) | WO2021184154A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| EP4161933A1 (en) * | 2020-06-08 | 2023-04-12 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
| CN114075190A (zh) * | 2020-08-20 | 2022-02-22 | 北京诺诚健华医药科技有限公司 | 杂环类btk抑制剂 |
| CN113861179A (zh) * | 2021-10-22 | 2021-12-31 | 上海应用技术大学 | 一种新型flt3激酶抑制剂及其合成与应用 |
| WO2025124429A1 (zh) * | 2023-12-11 | 2025-06-19 | 北京康辰药业股份有限公司 | 芳香胺化合物及其药物组合物、应用 |
| CN121039131A (zh) * | 2024-01-11 | 2025-11-28 | 佩勒梅德有限公司 | 新型吡咯并三嗪衍生物及其用途 |
| KR20250157634A (ko) | 2024-04-29 | 2025-11-05 | 대한민국(질병관리청 국립보건연구원장) | Bax 활성제를 유효성분으로 포함하는 항-hiv-1 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199902301T2 (xx) * | 1997-03-19 | 1999-12-21 | Basf Aktiengesellschaft | Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�. |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| ID29028A (id) * | 1998-09-18 | 2001-07-26 | Basf Ag | Pirolopirimidina sebagai penghambat protein kinase |
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| JP2003509428A (ja) * | 1999-09-17 | 2003-03-11 | アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー | 治療薬としてのピラゾロピリミジン |
| MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| WO2007064931A2 (en) * | 2005-12-02 | 2007-06-07 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
| ES2545907T3 (es) * | 2005-12-29 | 2015-09-16 | Abbvie Inc. | Inhibidores de proteína quinasa |
| SG10202107066WA (en) * | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
| JP6327713B2 (ja) * | 2012-07-27 | 2018-05-23 | 国立研究開発法人理化学研究所 | 急性骨髄性白血病の治療又は再発抑制剤 |
| USRE48175E1 (en) * | 2012-10-19 | 2020-08-25 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CN105017256A (zh) * | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| WO2016019237A2 (en) * | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US10266535B2 (en) * | 2015-01-21 | 2019-04-23 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Inhibitor of FLT3 kinase and use thereof |
| GB201508747D0 (en) | 2015-05-21 | 2015-07-01 | Univ Edinburgh | Compounds |
| JP2019529423A (ja) * | 2016-09-15 | 2019-10-17 | 国立研究開発法人理化学研究所 | 急性骨髄性白血病を処置するためのＨＣＫ阻害剤及びＢｃｌ−２阻害剤 |
| CN113544130B (zh) | 2019-05-31 | 2024-01-09 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| AU2020301399B2 (en) * | 2019-06-24 | 2025-12-18 | Dana-Farber Cancer Institute, Inc. | HCK degraders and uses thereof |
| KR20220098732A (ko) * | 2019-10-08 | 2022-07-12 | 다나-파버 캔서 인스티튜트 인크. | 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체 |
| MX2022008148A (es) * | 2020-01-02 | 2022-07-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Inhibidores de btk. |
| AU2020436612A1 (en) | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
-
2020
- 2020-03-16 AU AU2020436612A patent/AU2020436612A1/en active Pending
- 2020-03-16 WO PCT/CN2020/079464 patent/WO2021184154A1/en not_active Ceased
-
2021
- 2021-03-12 AR ARP210100645A patent/AR121570A1/es not_active Application Discontinuation
- 2021-03-15 AU AU2021239828A patent/AU2021239828B2/en active Active
- 2021-03-15 KR KR1020227035324A patent/KR20220154164A/ko active Pending
- 2021-03-15 JP JP2022555625A patent/JP7744358B2/ja active Active
- 2021-03-15 PH PH1/2022/552169A patent/PH12022552169A1/en unknown
- 2021-03-15 MX MX2022011407A patent/MX2022011407A/es unknown
- 2021-03-15 PE PE2022001990A patent/PE20230461A1/es unknown
- 2021-03-15 US US17/201,827 patent/US11963960B2/en active Active
- 2021-03-15 BR BR112022018345A patent/BR112022018345A2/pt not_active Application Discontinuation
- 2021-03-15 IL IL296296A patent/IL296296A/en unknown
- 2021-03-15 EP EP21772015.0A patent/EP4121430A4/en active Pending
- 2021-03-15 WO PCT/US2021/022322 patent/WO2021188417A1/en not_active Ceased
- 2021-03-15 CN CN202180016180.0A patent/CN115298180B/zh active Active
- 2021-03-15 CA CA3168988A patent/CA3168988A1/en active Pending
- 2021-03-16 TW TW110109254A patent/TWI899184B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518035A5 (enExample) | ||
| JP6505013B2 (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2026031940A (ja) | Ｓｈｐ２の活性を阻害するための化合物の製造方法 | |
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| CN101663282B (zh) | 包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物 | |
| WO2020160295A1 (en) | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | |
| JP2021534124A5 (enExample) | ||
| JP4220897B2 (ja) | ピペラジン化合物 | |
| JP2007505931A5 (enExample) | ||
| JP2023533447A5 (enExample) | ||
| JP2009537550A5 (enExample) | ||
| CN107660202B (zh) | 水溶性前药 | |
| ES3055488T3 (en) | Tegavivint for use in the treatment of pulmonary fibrosis | |
| JP2013537195A5 (ja) | 疾患を治療するための医薬品及び同医薬品を含むキット | |
| JP2022522486A5 (enExample) | ||
| JP2010521483A5 (enExample) | ||
| CN111344018B (zh) | 聚乙二醇化卡非佐米化合物的稳定的组合物 | |
| JP2015521617A5 (enExample) | ||
| JPWO2008099874A1 (ja) | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 | |
| JP2022537140A5 (enExample) | ||
| CN102482256B (zh) | N-取代的环状氨基衍生物 | |
| AU2020221247B2 (en) | Formulations comprising heterocyclic protein kinase inhibitors | |
| WO2020072955A1 (en) | Monomer and multimeric anti-hbv agents | |
| IL293703A (en) | Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms | |
| JP2012506908A5 (enExample) |